Skip to main content
FDA speeds up review of Gilead's HIV drug
8/11/2017
Joe Raedle/Getty Images

Gilead Sciences' new-drug application for a fixed-dose combination of bictegravir 50 mg and emtricitabine/tenofovir alafenamide 200 mg/25 mg received FDA priority-review status to treat HIV-1 infection, with an agency action date of Feb. 12, 2018.

Full Story: